But in real-world situations, such as when a bystander administers naloxone, there are gray areas.
Take these 4 steps to help prevent health conditions and disease naturally.
Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.
To eliminate the existing stigma in the community, addiction must be recognized as a treatable condition rather than an immoral act.
Pharmacists have always been a vital member of the cancer care team, but the emergence of many new oral therapies is making their role in patient care a more prominent one.
It’s essential that health care providers across the patient journey demystify the costs of treatment and provide solutions to overcome the financial barriers.
Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
The increasing economic burden of treatment may impact patient outcomes.
Pivotal resource helps health care professionals diagnose, manage, and prevent this group of lung diseases.
Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.
Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes.
Older adults, patients with weakened immune systems, individuals living in long-term facilities, and those with underlying cardiopulmonary disease are at a higher risk of developing severe RSV infection outcomes.
Becoming experts in medical billing for point-of-care testing offers a new avenue for technicians to excel and show their value.
Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.
Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Although robotics can be instrumental in assuring sterility and reducing the overall number of potential hazardous drug exposure events, certain tasks require vigilant oversight.
This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
As specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.
The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.
Transplant patients must adhere to lifelong regimens and those caring for them must consider their regimen as the patients intersect with different parts of the health care system.
Despite the proven efficacy of biosimilars, both patients and health care providers often have some reluctance when switching from an originator drug to a biosimilar.
It’s time for pharmacies to take a page out of the books of hospitals and tech companies by expanding and streamlining their use of contingent labor.
Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.
FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
As welcome as this compliance extension may be for those who qualify, it is critical they understand both their current and future regulatory obligations.
Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Beyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.
NADINA trial results support a new standard of care for these patients.